More data for PD-L1s avelumab, durvalumab

Abstracts released ahead of next month's American Society of Clinical Oncology (ASCO) meeting provided new objective response rate (ORR) data for two mAbs targeting PD-L1: avelumab ( MSB0010718C) from Merck KGaA (Xetra:MRK) and partner

Read the full 349 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE